BACKGROUND & AIMS: Little is known about long-term health outcomes of children with dyspeptic symptoms. We studied the natural history of pediatric patients with dyspeptic symptoms, with and without histologic reflux, compared with healthy controls. METHODS: We performed a prospective study of consecutive new patients, ages 8-16 years, who underwent evaluation for dyspepsia, including upper endoscopy. Patients were assigned to groups with histologic evidence of reflux esophagitis (n = 50), or normal histology results (n = 53). Healthy children were followed up as controls (n = 143). Patients and controls were evaluated 5-15 years later. They provided self-reports on severity of dyspeptic symptoms, use of acid suppression, quality of life, anxiety, and depression. RESULTS: When the study began, the groups with histologic evidence of esophagitis and normal histologies did not differ in severity of dyspeptic symptoms, functional disability, or depression. After a mean 7.6-year follow-up period, each group had significantly lower quality-of-life scores and more severe dyspeptic symptoms and functional disability than controls, but did not differ significantly from each other; both groups were significantly more likely than controls to meet criteria for an anxiety disorder. At time of follow-up evaluation, use of acid-suppression medication was significantly greater in the group with histologic evidence for esophagitis, compared with patients who had normal histology findings when the study began. CONCLUSIONS: Among pediatric patients with dyspepsia evaluated by endoscopy and biopsy, those with histologic evidence for esophagitis or normal histology findings are at increased risk for chronic dyspeptic symptoms, anxiety disorder, and reduced quality of life in adolescence and young adulthood.
BACKGROUND & AIMS: Little is known about long-term health outcomes of children with dyspeptic symptoms. We studied the natural history of pediatric patients with dyspeptic symptoms, with and without histologic reflux, compared with healthy controls. METHODS: We performed a prospective study of consecutive new patients, ages 8-16 years, who underwent evaluation for dyspepsia, including upper endoscopy. Patients were assigned to groups with histologic evidence of reflux esophagitis (n = 50), or normal histology results (n = 53). Healthy children were followed up as controls (n = 143). Patients and controls were evaluated 5-15 years later. They provided self-reports on severity of dyspeptic symptoms, use of acid suppression, quality of life, anxiety, and depression. RESULTS: When the study began, the groups with histologic evidence of esophagitis and normal histologies did not differ in severity of dyspeptic symptoms, functional disability, or depression. After a mean 7.6-year follow-up period, each group had significantly lower quality-of-life scores and more severe dyspeptic symptoms and functional disability than controls, but did not differ significantly from each other; both groups were significantly more likely than controls to meet criteria for an anxiety disorder. At time of follow-up evaluation, use of acid-suppression medication was significantly greater in the group with histologic evidence for esophagitis, compared with patients who had normal histology findings when the study began. CONCLUSIONS: Among pediatric patients with dyspepsia evaluated by endoscopy and biopsy, those with histologic evidence for esophagitis or normal histology findings are at increased risk for chronic dyspeptic symptoms, anxiety disorder, and reduced quality of life in adolescence and young adulthood.
Authors: P Aro; N J Talley; L Agréus; S-E Johansson; E Bolling-Sternevald; T Storskrubb; J Ronkainen Journal: Aliment Pharmacol Ther Date: 2011-03-28 Impact factor: 8.171
Authors: Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: A James Martin; Nicole Pratt; J Declan Kennedy; Philip Ryan; Richard E Ruffin; Helen Miles; John Marley Journal: Pediatrics Date: 2002-06 Impact factor: 7.124
Authors: Pertti Aro; Nicholas J Talley; Jukka Ronkainen; Tom Storskrubb; Michael Vieth; Sven-Erik Johansson; Elisabeth Bolling-Sternevald; Lars Agréus Journal: Gastroenterology Date: 2009-03-26 Impact factor: 22.682
Authors: John M Rosen; Jose T Cocjin; Jennifer V Schurman; Jennifer M Colombo; Craig A Friesen Journal: World J Gastrointest Pharmacol Ther Date: 2014-08-06
Authors: R Park; S Mikami; J LeClair; A Bollom; C Lembo; S Sethi; A Lembo; M Jones; V Cheng; E Friedlander; S Nurko Journal: Neurogastroenterol Motil Date: 2015-03-22 Impact factor: 3.598
Authors: Bruno P Chumpitazi; Erica M Weidler; Diana Y Lu; Cynthia M Tsai; Robert J Shulman Journal: J Acad Nutr Diet Date: 2016-06-15 Impact factor: 4.910
Authors: Lynn S Walker; Amanda L Stone; Craig A Smith; Stephen Bruehl; Judy Garber; Martina Puzanovova; André Diedrich Journal: Pain Date: 2017-08 Impact factor: 7.926